Jump to content

CSL - CSL LIMITED


ShareCafe

Recommended Posts

  • Replies 962
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

A misspelled one. Doesn't detract from the point I make however. The point of confusion was that both were/are federally sponsored. As are NZ's CRI's.

 

Imagine how the original investors must be feeling now. They must be in all the best graveyards around town.

 

Link to comment
Share on other sites

  • 2 weeks later...
A research note out of Morgan Stanley suggests CSL shares could hit $290 over the next 12 months with a bull case valuation of $359. The key to the bull case valuation is the healthcare giant's Phase 3 trial drug candidate CSL 112 as a treatment for heart attack patients.

 

It has three potential "catalytic events" over the next 18 months according to the analysts.

 

Morgan Stanley is forecasting the group will deliver $US4.68 in earnings per share (EPS) over fiscal 2020 on revenue of US$9,129 million. For fiscal 2021 it expects EPS to climb to $US5.50 on revenue of $US10,231 million.

 

In total it's tipping growing immunoglobulin sales to help deliver a 3-year compound EPS annual growth rate of 13 per cent with fiscal 2020 "above or at the top end of guidance.

Link to comment
Share on other sites

  • 2 weeks later...
  • 3 weeks later...

CSL achieved 11 per cent net profit growth of $US1.248 billion and earnings of $US2.75 a share.

 

The company declared an interim dividend of US95Ãâہ¡ÃƒÆ’‚¢ and forecast 2019-20 net profit of $US2.11 billion to $US2.17 billion, up 10 to 13 per cent year-on-year

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...